Skip to main content

Table 1 Demographic and clinical characteristics of patients

From: Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series

Characteristic Patients (N = 8)
Median age (IQR), years 60.5 (47.5–68.5)
Male sex, no. (%) 4 (50.0)
Oxygen support, no. (%) 0
Body mass index (kg/m2), median (IQR) 22.2 (20.0–26.8)
Median duration of positive RNA detection before favipiravir therapy (days), median (IQR) 61.0 (52.8–67.3)
Other therapies before favipiravir therapy, no. (%)
 Chloroquine phosphate 4 (50.0)
 Umifenovir 3 (37.5)
 Entecavir 1 (12.5)
 Lianhua Qingwen granules 2 (25.0)
 Thymopeptides 4 (50.0)
 Pidotimod 4 (50.0)
 Plasma transfusion 2 (25.0)
Coexisting conditions, no. (%)
 Any condition 6 (75.0)
 Hypertension 4 (50.0)
 Diabetes 2 (25.0)
 Coronary heart disease 1 (12.5)
 Malignant tumor 2 (25.0)
Immunoglobulin level (AU/mL), median (IQR)
 IgM 12.5 (5.1–25.2)
 IgG 102.7 (56.1–162.5)
  1. IgG immunoglobulin G, IgM immunoglobulin M, IQR interquartile range